Targeted DNA/RNA Sequencing Market Worth $15.9 Billion by 2025: Grand View Research, Inc.

News provided by

Grand View Research, Inc.

10 Oct, 2017, 10:30 BST

SAN FRANCISCO, October 10, 2017 /PRNewswire/ --

The global targeted DNA/RNA sequencing market is expected to reach USD 15.9 billion by 2025, according to a new report by Grand View Research, Inc. Targeted Sequencing has emerged as a key technology in life science research by enabling examination of specific region of interest while keeping the seq. cost as well as complexity of data under manageable limits.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

This approach enhances sequencing depth by allowing evaluation of specific coding regions within genes or specific genes, which are known to harbor mutations for disease pathogenesis. Several research projects have employed this technology to avoid wastage of information and extra cost and study only relevant genes. Number of such projects continue to grow, consequently driving the market.

Innovations to address the pitfalls of targeted enrichment method are anticipated to enhance the usage rate of this technology throughout the forecast period. Moreover, with decrease in seq-cost and improvement in informatics, targeted methods have become more accessible for use in clinical settings than ever.

Browse full research report with TOC on "Targeted DNA/RNA Sequencing Market Analysis By Technology (NGS, Exome Sequencing Seq., Enrichment Seq., Amplicon Seq., Sanger Seq.), By Workflow, By Application, By Type, By End-use, And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/targeted-dna-rna-sequencing-market

Further Key Findings From the Report Suggest: 

  • Next-Generation Sequencing (NGS) technology captured a major share in 2016
  • Rapid advancements in NGS and its ancillary protocols can be attributed to the growth of this segment
  • Out of all the NGS-based targeted methods, exome-seq held the largest share
  • This can be attributed to the fact that though it accounts for less than 2% of the genome, it contains 85% of the known disease-relevant variants
  • Entire targeted approach is broken down into presequencing, sequence determination, and data analysis
  • Being the most crucial step, sequencing accounted for the largest share
  • This space has revolutionized various applications of life sciences, including human biomedical research, plant & animal sciences, drug discovery, and others
  • Out of all, human biomedical research is estimated to be the largest application of this space due its high usage in studying disease pathogenesis
  • The market is bifurcated into DNA-seq and RNA-seq, based on the sample type
  • DNA-sequencing has been estimated to generate the higher revenue over its counterpart segment. This can be attributed to the presence of wide range of products and kits for DNA-seq
  • As per end use, academic research is estimated to be the largest segment owing to the increase in seq-based projects at universities and other academic centers
  • North America held the largest share owing to the presence of effective regulations pertaining to approval of genetic tests and bioinformatics tools
  • Moreover, the U.S. is observed to have highest number of installed sequencers, which in turn, has contributed to the large share of North America regional market
  • Asia Pacific is expected to emerge as the fastest growing regional market
  • Rise in genome-based projects coupled with constant GDP growth in Asian countries is expected to drive the Asia Pacific market
  • Illumina, Inc.; F. Hoffmann-La Roche Ltd; QIAGEN, Thermo Fisher Scientific, Inc.; and Oxford Nanopore Technologies are some of the major companies operating in this space

Browse related reports by Grand View Research: 

Grand View Research has segmented the global targeted DNA/RNA sequencing market on the basis of technology, workflow, application, type, end use, and region: 

  • Technology Outlook (Revenue, USD Million, 2014 - 2025) 
    • Next-generation Sequencing (NGS)
      • By Methods
        • Exome Sequencing
        • Enrichment Sequencing
        • Amplicon Sequencing
        • Others
      • By Applications
        • Cancer Gene Sequencing
        • Inherited Disease Screening
        • Drug Development
        • Forensic Genomics
        • 16S ribosomal RNA (rRNA) sequencing
    • Others
  • Workflow Outlook (Revenue, USD Million, 2014 - 2025) 
    • Presequencing
    • Sequencing
    • Data Analysis
  • Application Outlook (Revenue, USD Million, 2014 - 2025) 
    • Human Biomedical Research
    • Plant & Animal Sciences
    • Drug Discovery
    • Others
  • Type Outlook (Revenue, USD Million, 2014 - 2025) 
    • DNA-based Targeted Sequencing
    • RNA-based Targeted Sequencing
  • End-use Outlook (Revenue, USD Million, 2014 - 2025) 
    • Academic Research
    • Hospitals & Clinics
    • Pharma & Biotech Entities
    • Other Users
  • Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
    • Middle East & Africa
      • South Africa

Read Our Blog By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.